Top Tweets for #windlas
6 . Windlas Biotech Ltd 🔖
#windlas
🚀Change In Promoters Holding ~1.32 %
Mar 2025~61.90%🔥
May 2026 ~63.31% 🔥
#Windlas In short term, market punishes a stock for P&L underperformance. However, some short term accounting underperformance are for real long term gains. Professionalizing a small company by rewarding employees for performance incentive ESOPs is one though its accounting makes P&L look bad.
Same management comes with buyback without promoter participation
Managements keep giving signals of who they are
Investors/Traders need to choose with whom and for how long they want to tag along
Note: Not a buy or sell recommendation. Under coverage.
#WINDLAS 819
Doing wave 4..
Breakout needed from the upper trendline to confirm 5th up..
5th can do 1500 whenever it will start its 5th.
*Use Discretion.
#Healthcare
@alarnath Windlas chart plz
#WINDLAS Windlas Biotech Ltd Management Mirror Report
Track what management says quarter after quarter, and spot exactly when the story starts to change
Live for Q4FY26 earnings season. Free trial at https://t.co/fHfrkOxaSX
#WINDLAS #WINDLASQ4 Windlas Biotech Ltd Q4FY26 Earnings Concall Summary (Extract) | Subscribe on our website for Instant delivery (Detailed) via WhatsApp & Email
Windlas Biotech Ltd Q4FY26 Results:-
#Q4Results #Q4FY26 #Stockmarket #Nifty #Windlas
Revenue 238.50 Cr vs 202.71 Cr
(+17.66% YoY┃+2.32% QoQ)
EBITDA 25.29 Cr vs 25.55 Cr
(-1.03% YoY ┃+3.72% QoQ)
EBITDA Margin 10.60% vs 12.60% YoY & 10.46% QoQ
PBT 20.16 Cr vs 20.82 Cr
(-3.18% YoY┃+0.95% QoQ)
PAT 15.99 Cr vs 16.28 Cr
(-1.79% YoY┃+6.59% QoQ)
Other Income 4.35 Cr vs 4.94 Cr YoY & 4.57 Cr QoQ
Windlas Biotech Ltd - Buyback Update
Day 2 bid details for the ongoing share buyback are below.
Follow us for keep tracking the demand trends closely!
#buyback #windlas #stocktowatch #StockPortfolio
Windlas Biotech Ltd : In board meeting, the company announced the following terms and conditions of the share buyback.
#sharebuyback #Windlas #windlasbuyback #boardmeeting
Windlas Biotech Ltd : Company Board confirm board meeting on 17 April 2026 to consider buyback of shares.
CMP : INR 865
Mkt Cap : 1,826 cr
#windlas #windlasbuyback #buybackwindlas #sharebuyback #buyback
📅 Street Pulse Recap: APRIL 17, 2026
Major Announcements for #ULTRACEMCO #JSWSTEEL #NBCC #BOSCHLTD #NTPCGREEN #DREDGECORP #ABREL #AUROPHARMA #MOREPENLAB #WINDLAS & more!
#StocksToWatch #Watchlist #Trading
#StockInNews | Windlas Biotech board approves buyback of 4.70 lk shares (2.23% Eq) at ₹1,000/sh
#WINDLAS #StockMarket
Upcoming #Buyback
#Aurobindo Pharma : Rush is you want to participate as record day is near
#Wipro
#Windlas Biotech
#Cyient
#Specialsituation
I am not an RIA and not recommending to buy or sell.
Windlas Biotech Ltd : Company Board confirm board meeting on 17 April 2026 to consider buyback of shares.
CMP : INR 865
Mkt Cap : 1,826 cr
#windlas #windlasbuyback #buybackwindlas #sharebuyback #buyback
#Windlas :
CDMO growth is 23% YoY and Exports are up by 36% YoY ( Very low base )
Trade Generics are 7% YoY , Lower than Q2 .
But still revenue growth is much resilient.
EBITDA excluding ESOP up by 26% YoY.
ESOP paid will last till Dec 2027
Windlas Biotech Limited Q3 FY26 Results:-
Revenue 233.10 Cr vs 195.02 Cr
(+19.53% YoY┃+4.81% QoQ)
PAT 15.00 Cr vs 15.58 Cr
(-3.69% YoY┃-15.72% QoQ)
#Q3Results #Q3FY26 #Stockmarket #Nifty #windlas
Pick of the Week: Windlas
Target ₹1000-1100 | Upside 31% | Timeframe 10–12 weeks
Read Blog : https://t.co/fLXPrrgR9s
#pickoftheweek #Windlas #equityresearch #equityideas #monarchnetworth
#Windlas Biotech clocked a solid 13% EBITDA margin in H1 FY26 but expects it to slip to ~10% in H2 as "headwinds" bite. The Q2 FY26 earnings transcript explains why.
Discl: purely an opinion; no recommendation whatsoever!
#pharma #windlas #CDMO
✅Windlas Biotech - currently executing a complex but promising scale up.
👉Last one year confirms that it has pivoted from a contract manufacturer to a diversified pharma manufacturing platform with robust demand drivers across CDMO, Trade Generics and Exports
🤝Key takeaways from H1 performance and interpretation of the commentary
1. The capex deployment is on in full swing and the demand is good, 19% revenue growth in H1. Windlas is aligned with right therapeutic segments. Working capital cycle likely to expand from current super efficient 14 days.
2. Profitability is temporarily masked which is a function of growth investments - New Plants + ESOPs for top 100 Managers. Gross margin compression is under our scanner.
3. FY '27 will be the year of full capacity of Injectables Plant and maturation of Export dossier pipeline. Despite the heavy capex, the company remains debt free with net-to-equity ratio of -0.41
⚙️Looks like a good play with every quarter's results needing dissection. FY'27 is the key for profitability growth, backed by an already robust balance sheet
#Sector #investing #H1results #generics #exports #StocksToWatch
Windlas Biotech Limited Q2 FY26 :-
#Q2Results #Q2FY26 #stockmarket #nifty #windlas
Q2
Revenue +18.9% YoY
EBITDA +23.9% YoY
EBITDA Margin 12.7% vs 12.1% YoY
PAT +13.7% YoY
Business Segment Performance:-
Generic Formulations CDMO +17.7% YoY
Trade Generics & Institutional +24.2% YoY
Exports +13.0% YoY
Key Highlights:-
11th consecutive quarter of record revenue performance.
Highest-ever half-yearly revenue at ₹432 crore and highest-ever EBITDA at ₹55 crore.
Balanced growth across all three verticals: CDMO, Trade Generics, and Exports.
Gross margin improvement: +68 bps YoY in Q2 and +70 bps YoY in H1, supported by scale and product mix.
Dividend: ₹12.2 crore (₹5.8/share) paid for FY25.
Strong liquidity: ₹237 crore and net operating cash flow of ₹56 crore in H1FY26.
Operational Updates:-
Plant-2 extension, commissioned in Q4FY25, now contributing meaningfully
Injectables facility gaining traction with customer approvals and commercial ramp-up in both CDMO and Trade Generics segments
Plant-6 expansion progressing well, expected commissioning within FY26
ESOP 2025 Scheme: ₹1.2 crore non-cash expense recognized in Q2FY26
Management Commentary:-
We’ve delivered our 11th consecutive quarter of record revenue with 19% YoY growth in both Q2 and H1 FY26.
This performance was broad-based across all segments, despite modest industry growth.
Our strong focus on quality, capacity expansion, and diversification continues to drive value creation
With ₹237 crore cash and a healthy order book, we are well positioned for continued expansion and shareholder value creation
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.7M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82.1M followers
Lady Gaga
@ladygaga
73.6M followers
Virat Kohli
@imvkohli
70.8M followers
Kim Kardashian
@kimkardashian
70.1M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.7M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.3M followers
X
@x
60.8M followers